Three key opinion leaders will make much-needed advancements in treatment options for Inflammatory Bowel Disease on new advisory panel.
We are innovating to help humanity achieve some of its most inspiring medical advancements in the 21st century. Read about Microba’s progress, partnership news and latest discoveries.
Published study found a method designed for preserving forensic DNA outperformed other commonly used faecal preservation methods.
Microba Community Profiler (MCP) outperforms existing profilers for accurate and comprehensive characterisation of the human gut microbiome.
Mark Capone to strengthen diagnostics platform with 35-year career in life sciences and molecular diagnostics.
Microba’s commitment to developing life-changing therapeutics derived from the gut microbiome will add a valuable voice to MTIG’s mission.
Microba have partnered with Europe’s largest pathology provider, SYNLAB, to deliver leading gut microbiome analysis into Europe.
Microba launched an IBD Research and Development (R&D) program in 2019 to tackle IBD by mining the gut microbiome for novel biotherapeutics.
Professor Phil Hugenholtz, has been announced as the next Vice President of the International Society for Microbial Ecology (ISME).
Microba have partnered with US company Psomagen to deliver gut microbiome analysis technology to the US market.